SWAV Investors, You Need to Know These Facts Today.

Mid-cap Health Care company ShockWave Medical has moved 0.4% so far today on a volume of 41,673, compared to its average of 500,755. In contrast, the S&P 500 index moved 0.0%.

ShockWave Medical trades -1.15% away from its average analyst target price of $255.11 per share. The 9 analysts following the stock have set target prices ranging from $165.0 to $285.0, and on average have given ShockWave Medical a rating of buy.

Anyone interested in buying SWAV should be aware of the facts below:

  • ShockWave Medical's current price is 2363.6% above its Graham number of $10.24, which implies that at its current valuation it does not offer a margin of safety

  • ShockWave Medical has moved 18.2% over the last year, and the S&P 500 logged a change of -7.6%

  • Based on its trailing earnings per share of 5.69, ShockWave Medical has a trailing 12 month Price to Earnings (P/E) ratio of 44.3 while the S&P 500 average is 15.97

  • SWAV has a forward P/E ratio of 56.4 based on its forward 12 month price to earnings (EPS) of $4.47 per share

  • The company has a price to earnings growth (PEG) ratio of 0.85 — a number near or below 1 signifying that ShockWave Medical is fairly valued compared to its estimated growth potential

  • Its Price to Book (P/B) ratio is 17.9 compared to its sector average of 4.16

  • ShockWave Medical, Inc., a medical device company, develops intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally.

  • Based in Santa Clara, the company has 1,001 full time employees and a market cap of $9,203,045,376.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS